ETR:SRT - Sartorius Stock Price, News, & Analysis

Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors. It also provides lab filtration and purification devices; sterile and virus filtration, crossflow filtration, harvesting, prefiltration, membrane chromatography, air/gas filtration, and integrity testing devices; and liquid storage and shipping, freeze and thaw, mixing, proven integrity, transferring and sampling, connecting and disconnecting, and final filling management products. In addition, the company offers process control and data analytics products, such as process analyzers, automation modules, and data analytics and chemometrics; and microbiology products, and lab water purification systems. Further, it provides lab balances, mass comparators and metrology, moisture analyzers, specialty weighing solutions, weighing accessories, weights/weight sets, paint mixing solutions, and OEM weigh cells; and OEM membrane and device, pipetting and dispensing, and connectivity solutions. Additionally, the company offers bioprocess development engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, food and beverage, environmental, and paint mixing industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

Sartorius (ETR:SRT) Frequently Asked Questions

What is Sartorius' stock symbol?

Sartorius trades on the ETR under the ticker symbol "SRT."

When is Sartorius' next earnings date?

Sartorius is scheduled to release their next quarterly earnings announcement on Monday, July 22nd 2019. View Earnings Estimates for Sartorius.

What price target have analysts set for SRT?

8 equities research analysts have issued twelve-month target prices for Sartorius' stock. Their forecasts range from €93.00 to €142.00. On average, they anticipate Sartorius' stock price to reach €114.88 in the next year. This suggests that the stock has a possible downside of 25.6%. View Analyst Price Targets for Sartorius.

What is the consensus analysts' recommendation for Sartorius?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sartorius in the last year. There are currently 4 sell ratings and 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sartorius.

Has Sartorius been receiving favorable news coverage?

News headlines about SRT stock have been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sartorius earned a coverage optimism score of 0.7 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.

Who are some of Sartorius' key competitors?

Some companies that are related to Sartorius include Siemens Healthineers (SHL), Carl Zeiss Meditec (AFX), NationalResearchCorp . (NRC), Integral Diagnostics (IDX), Senseonics (SENS), Senseonics (SENS), Akumin (AKU), Palatin Technologies (PTN), Renalytix Ai (RENX), Profound Medical (PRN), MaxCyte (MXCT), Yourgene Health (YGEN), Oncimmune (ONC), Lexagene (LXG) and Oncosil Medical (OSL).

What other stocks do shareholders of Sartorius own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sartorius investors own include Align Technology (ALGN), Cytokinetics (CYTK), Endologix (ELGX), American Eagle Outfitters (AEO), Select Energy Services (WTTR), Headlam Group (HEAD), Gaming Realms (GMR), Diageo (DGE), DCC (DCC) and Fresenius SE & Co KGaA (FRE).

Who are Sartorius' key executives?

Sartorius' management team includes the folowing people:

• Dr. Joachim Kreuzburg, Chairman of Exec. Board & CEO (Age 54)
• Mr. Rainer Lehmann, CFO & Member of Exec. Board and Head of Fin., Information Technology & Bus. Process (Age 43)
• Ms. Petra Kirchhoff, Head of Corp. Communications & Investor Relations and Member of Supervisory Board (Age 50)
• Mr. Gerry Mackay, Head of Lab Products & Services Division & Member of Exec. Board (Age 56)
• Dr. René Fáber, Head of Bioprocess Solutions Division & Member of Exec. Board (Age 43)

What is Sartorius' stock price today?

One share of SRT stock can currently be purchased for approximately €154.50.

How big of a company is Sartorius?

Sartorius has a market capitalization of $10.57 billion and generates $1.64 billion in revenue each year. Sartorius employs 8,125 workers across the globe.

What is Sartorius' official website?

The official website for Sartorius is http://www.sartorius.com/.

How can I contact Sartorius?

The company can be reached via phone at 49 551 308 0.